Savara (NASDAQ:SVRA) Trading Up 4.8%

Savara Inc (NASDAQ:SVRA) shares shot up 4.8% during trading on Wednesday . The company traded as high as $4.50 and last traded at $4.41. 233,532 shares were traded during mid-day trading, a decline of 81% from the average session volume of 1,211,780 shares. The stock had previously closed at $4.21.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SVRA. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Savara in a research report on Wednesday, August 14th. Evercore ISI dropped their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, May 16th. Guggenheim lifted their price objective on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Oppenheimer lifted their price objective on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a report on Wednesday, June 26th. Finally, JMP Securities cut their price objective on Savara from $10.00 to $9.00 and set a “market outperform” rating for the company in a report on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara presently has an average rating of “Buy” and an average price target of $11.17.

Savara Stock Up 3.6 %

The firm has a fifty day moving average of $4.40 and a 200 day moving average of $4.56. The stock has a market cap of $717.66 million, a PE ratio of -12.08 and a beta of 1.00. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). On average, equities research analysts anticipate that Savara Inc will post -0.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. ProShare Advisors LLC grew its stake in Savara by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after buying an additional 2,114 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after purchasing an additional 4,625 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Savara by 14.9% in the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after acquiring an additional 5,335 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co bought a new position in Savara in the 1st quarter valued at $35,000. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.